Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Higia Technologies is a Mexican healthcare technology company focused on the early detection of breast cancer through non-invasive, AI-powered screening. The company's flagship product, EVA, is a wearable biosensor insert for bras that uses thermal mapping and artificial intelligence to detect abnormal temperature patterns associated with tumor growth. Founded by Julián Ríos Cantú, the company has expanded its business model to include 'Eva Center' specialized clinics that offer screenings and medical consultations. The technology is designed to provide a more accessible and comfortable alternative or supplement to traditional mammography, particularly for younger women with dense breast tissue. Higia aims to improve survival rates by making breast cancer monitoring more frequent, painless, and effective.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Higia.